Morgan Stanley Reiterates Overweight, Raises Price Target On Valeant Pharmaceuticals On New Proforma Model For SLXP
February 26, 2015 at 09:22 AM EST
In a report published Thursday, Morgan Stanley analyst David Risinger reiterated an Overweight rating on Valeant Pharmaceuticals (NYSE: ...
